Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs
Open Access
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (3) , 101033
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Thomas Jefferson University
This publication has 49 references indexed in Scilit:
- An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancerAmerican Journal of Hematology, 2019
- Current Progress in CAR-T Cell Therapy for Solid TumorsInternational Journal of Biological Sciences, 2019
- Fundamental Mechanisms of Immune Checkpoint Blockade TherapyCancer Discovery, 2018
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasNew England Journal of Medicine, 2017
- Engineering CAR-T cellsBiomarker Research, 2017
- Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironmentJournal for ImmunoTherapy of Cancer, 2017
- The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic StrategyInternational Journal of Molecular Sciences, 2017
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensNature, 2014
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Immunotherapy of Melanoma Targeting Human High Molecular Weight Melanoma‐Associated Antigen: Potential Role of Nonimmunological MechanismsAnnals of the New York Academy of Sciences, 2004